The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma

Stephen Broski, Christopher H. Hunt, Geoffrey B. Johnson, Ratham M. Subramaniam, Patrick J. Peller

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the clinical utility of 18F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. Methods: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. Results: Twenty-eight patients (mean age, 52.3 ± 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 ± 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 ± 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P = 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%) of 28 esthesioneuroblastoma patients. Of these, 10 (36%) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and distant metastases in 2 (7%) of 28, and distant metastases in 1 (4%) of 28. One patient (4%) was downstaged after negative findings on PET/CT. Conclusion: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.

Original languageEnglish (US)
Pages (from-to)1200-1206
Number of pages7
JournalJournal of Nuclear Medicine
Volume53
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Olfactory Esthesioneuroblastoma
Fluorodeoxyglucose F18
Neoplasm Metastasis
Recurrence
Neoplasms
Research Ethics Committees
Medical Records

Keywords

  • Esthesioneuroblastoma
  • Olfactory neuroblastoma
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. / Broski, Stephen; Hunt, Christopher H.; Johnson, Geoffrey B.; Subramaniam, Ratham M.; Peller, Patrick J.

In: Journal of Nuclear Medicine, Vol. 53, No. 8, 01.08.2012, p. 1200-1206.

Research output: Contribution to journalArticle

Broski, Stephen ; Hunt, Christopher H. ; Johnson, Geoffrey B. ; Subramaniam, Ratham M. ; Peller, Patrick J. / The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. In: Journal of Nuclear Medicine. 2012 ; Vol. 53, No. 8. pp. 1200-1206.
@article{55c14d1a03fe4b3787faf983d6595f0e,
title = "The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma",
abstract = "The purpose of this study was to evaluate the clinical utility of 18F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. Methods: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. Results: Twenty-eight patients (mean age, 52.3 ± 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 ± 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 ± 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P = 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39{\%}) of 28 esthesioneuroblastoma patients. Of these, 10 (36{\%}) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18{\%}) of 28, local recurrence in 2 (7{\%}) of 28, cervical nodal and distant metastases in 2 (7{\%}) of 28, and distant metastases in 1 (4{\%}) of 28. One patient (4{\%}) was downstaged after negative findings on PET/CT. Conclusion: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.",
keywords = "Esthesioneuroblastoma, Olfactory neuroblastoma, PET/CT",
author = "Stephen Broski and Hunt, {Christopher H.} and Johnson, {Geoffrey B.} and Subramaniam, {Ratham M.} and Peller, {Patrick J.}",
year = "2012",
month = "8",
day = "1",
doi = "10.2967/jnumed.112.102897",
language = "English (US)",
volume = "53",
pages = "1200--1206",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma

AU - Broski, Stephen

AU - Hunt, Christopher H.

AU - Johnson, Geoffrey B.

AU - Subramaniam, Ratham M.

AU - Peller, Patrick J.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The purpose of this study was to evaluate the clinical utility of 18F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. Methods: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. Results: Twenty-eight patients (mean age, 52.3 ± 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 ± 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 ± 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P = 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%) of 28 esthesioneuroblastoma patients. Of these, 10 (36%) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and distant metastases in 2 (7%) of 28, and distant metastases in 1 (4%) of 28. One patient (4%) was downstaged after negative findings on PET/CT. Conclusion: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.

AB - The purpose of this study was to evaluate the clinical utility of 18F-FDG PET/CT in esthesioneuroblastoma staging and restaging and quantify the additional benefit of PET/CT to conventional imaging. Methods: A retrospective review was performed with institutional review board approval for patients with a diagnosis of esthesioneuroblastoma who underwent PET/CT from 2000 to 2010. PET/CT results were retrospectively reviewed by 2 radiologists who were unaware of the clinical and imaging data. Positive imaging findings were classified into 3 categories: local disease, cervical nodal spread, and distant metastasis. All conventional imaging performed in the 6 mo preceding PET/CT, and the medical records, were reviewed to determine the potential added value. Results: Twenty-eight patients (mean age, 52.3 ± 10 y; range, 23-81 y) were identified who underwent a total of 77 PET/CT examinations. Maximum standardized uptake value (SUVmax) was 8.68 ± 4.75 (range, 3.6-23.3) for the primary tumor and 8.57 ± 6.46 (range, 1.9-27.2) for the metastatic site. There was no clear association between primary tumor SUVmax and tumor grade (P = 0.30). Compared with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%) of 28 esthesioneuroblastoma patients. Of these, 10 (36%) of 28 were upstaged on the basis of their PET/CT studies. Cervical nodal metastases were found in 5 (18%) of 28, local recurrence in 2 (7%) of 28, cervical nodal and distant metastases in 2 (7%) of 28, and distant metastases in 1 (4%) of 28. One patient (4%) was downstaged after negative findings on PET/CT. Conclusion: PET/CT is a useful adjunct to conventional imaging in the initial staging and restaging of esthesioneuroblastoma by detecting nodal and distant metastatic disease not demonstrated by conventional imaging and identifying local recurrence hidden by treatment changes on conventional imaging.

KW - Esthesioneuroblastoma

KW - Olfactory neuroblastoma

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=84864777545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864777545&partnerID=8YFLogxK

U2 - 10.2967/jnumed.112.102897

DO - 10.2967/jnumed.112.102897

M3 - Article

C2 - 22728262

AN - SCOPUS:84864777545

VL - 53

SP - 1200

EP - 1206

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -